Bringing the Treatment of Atopic Eczema Into a New Era with Janus Kinase  Inhibitors: A Position Statement By the Persatuan Dermatologi Malaysia

Noor Zalmy Azizan; Adawiyah Jamil; Chang Choong Chor; Dawn Ambrose; Henry Foong Boon Bee; How Kang Nien; Rajalingam Ramalingam; Sabeera Begum Bt Kader Ibrahim; Sharifah Rosniza Binti Syed Nong Chek; Tan Wooi Chiang; Wong Hoi Ling

Return

Bringing the Treatment of Atopic Eczema Into a New Era with Janus Kinase Inhibitors: A Position Statement By the Persatuan Dermatologi Malaysia

Author: Noor Zalmy Azizan ¹ ; Adawiyah Jamil ² ; Chang Choong Chor ³ ; Dawn Ambrose ⁴ ; Henry Foong Boon Bee ⁵ ; How Kang Nien ⁶ ; Rajalingam Ramalingam ⁷ ; Sabeera Begum Bt Kader Ibrahim ⁸ ; Sharifah Rosniza Binti Syed Nong Chek ¹ ; Tan Wooi Chiang ⁹ ; Wong Hoi Ling ¹⁰
Author Information

1. Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
2. Hospital Canselor Tuanku Muhriz, UKM, Kuala Lumpur, Malaysia
3. Gleneagles Kuala Lumpur, Malaysia
4. Hospital Pantai Kuala Lumpur, Malaysia
5. Foong Skin Specialist Clinic, Ipoh, Malaysia
6. Hospital Pengajar Universiti Putra Malaysia, Serdang, Malaysia
7. Hospital Tengku Ampuan Afzan, Kuantan, Malaysia
8. Hospital Tunku Azizah, Kuala Lumpur, Malaysia
9. Hospital Pulau Pinang, Pulau Pinang, Malaysia
10. Hospital Wanita dan Kanak-kanak, Kota Kinabalu, Sabah, Malaysia
Publication Type:Journal Article
Keywords: Atopic dermatitis; JAK-i; Recommendations
MeSH: Dermatitis, Atopic--therapy; Janus Kinase Inhibitors
From:Malaysian Journal of Dermatology 2022;49(Dec 2022):2-11
CountryMalaysia
Language:English
Abstract: Abstract:Atopic eczema (AE) is a complex, chronic and recurrent inflammatory pruritic skin condition that impacts the quality of life and exerts an economic toll on patients and their families. One of the factors contributing to AE is the immune dysregulation of the Janus kinase-signal transducers and activators of transcription (JAK-STAT) inflammatory pathway. This has prompted the conduct of various large clinical trial programs to evaluate the efficacy and safety of Janus kinase inhibitors (JAK-i) for AE. The overall and significant benefit of these drugs from clinical studies resulted in regulatory approvals for JAK-i to treat moderate-to-severe atopic eczema. The objective of this position paper was to evaluate the safety, efficacy and role of upadacitinib, baricitinib and abrocitinib in managing AE and update the current recommended treatment algorithm within the 2018 Malaysian Clinical Practice Guidelines for the Management of Atopic Eczema. The Persatuan Dermatologi Malaysia recommends that these JAK-i can be considered as an option for systemic therapy in severe AE.
Full text:15.2022my0012.pdf